US Patent Issued to ONECUREGEN on Jan. 27 for "Disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition for suppressing cancer growth comprising same as active ingredient" (South Korean Inventors)

ALEXANDRIA, Va., Jan. 28 -- United States Patent no. 12,534,436, issued on Jan. 27, was assigned to ONECUREGEN Co. LTD. (Daejeon, South Korea).

"Disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition for suppressing cancer growth comprising same as active ingredient" was invented by Kyeong Lee (Ilsan, South Korea), Mi Sun Won (Daejeon, South Korea), Hyun-Seung Ban (Daejeon, South Korea), Min Kyoung Kim (Suwon, South Korea) and Bo-Kyung Kim (Daejeon, South Korea).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to: a disubstituted adamantyl derivative or a pharmaceutically acceptable salt thereof, and an anticancer pharmaceutic...